How Germer International helped a mid-size specialty pharma compete for talent against Merck and Hoffmann-La Roche — on the way to a $3.7 billion sale to Abbott.
| Client | Kos Pharmaceuticals |
|---|---|
| Industry | Specialty pharmaceuticals |
| Partnership | 2003–2006 |
| Germer’s Focus | Quality Assurance and regulatory/compliance talent |
| Placements | ~ 60 professionals, the large majority in Quality Assurance |
| Outcome | Acquired by Abbott Laboratories for approx $3.7 billion (2006) |
THE CHALLENGE
Kos Pharmaceuticals built its business by reformulating existing drugs — including Niaspan and Advicor — into better treatments for chronic cardiovascular and metabolic disease. But in the pharma job market of the early 2000s, Kos was competing for talent against the biggest names in the industry. “There was a huge class system in pharma then,” recalls John Germer, founder and CEO of Germer International. Candidates with options at companies like Merck or Hoffmann-La Roche saw little reason to bet their careers on a smaller, less established name — even one doing genuinely innovative work.
THE APPROACH
Germer became Kos’s specialized recruiting partner for the roles the company could least afford to get wrong: Quality Assurance and the regulatory-facing functions that keep a pharmaceutical manufacturer in the FDA’s good graces. Over the course of the engagement, Germer placed roughly 60 professionals at Kos, the large majority in QA, along with a senior HR leader. The job wasn’t just sourcing candidates — it was convincing them. “It’s really bringing that commercial credibility right into their face,” John says of persuading talent to look past a company’s size and consider what it was actually building.
“Without the best QA, you don’t have a company. If you can’t get people who know how to document things and report to the FDA, eventually you’re going to get shut down. That’s where the real pain point was for their company.”
— John Germer, Founder & CEO, Germer International
THE RESULT
Kos Pharmaceuticals was acquired by Abbott Laboratories in December 2006 for approximately $3.7 billion — one of the largest specialty pharma acquisitions of its era. Germer’s engagement wound down cleanly once the deal closed.
Germer International is applying the same playbook today with other generic pharmaceutical manufacturers and life sciences companies working toward similar outcomes.
* * *
Germer International specializes in executive and professional search for pharmaceutical, biotech, medical device, and nutraceutical companies. Germer International also partners with Private Equity and Venture investors in the space to help mitigate risk and find the best talent to spur growth and stability at their portfolio companies. To learn how Germer’s approach could support your next stage of growth, contact the firm today.

